<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24990" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Menstrual-Related Headache</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moy</surname>
            <given-names>Gregory</given-names>
          </name>
          <aff>North Shore University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gregory Moy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24990.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Menstrual-related headaches (MRH) are a common class of headaches that occur in women related to a decline in estrogen during the menstrual cycle. Menstrual-related headaches are related to several important factors, mainly estrogen, which has actions involved in the serotonergic and glutamatergic systems of the CNS. To treat this type of headache, it must be appropriately diagnosed relative to the menstrual cycle or aligned with exogenous hormones, usually two days before the onset of menses to the third day of menstrual bleeding. This activity reviews the evaluation and treatment of MRH and highlights the role of the interprofessional team in the care of patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of menstrual-related migraines.</p></list-item><list-item><p>Assess&#x000a0;the physical exam findings in menstrual-related migraines.</p></list-item><list-item><p>Evaluate&#x000a0;the medical management of menstrual-related migraines.</p></list-item><list-item><p>Communicate the importance of improving care coordination among the interprofessional team to enhance care delivery for patients with menstrual-related migraines.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24990&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24990">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24990.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Menstrual-related headaches are a common class of headaches that occur in women related to a decline in estrogen during the menstrual cycle. To treat this type of headache, it must be appropriately diagnosed regarding the menstrual cycle or aligned with exogenous hormones, usually&#x000a0;2 days before the onset of menses to the third day of menstrual bleeding. Triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and hormone therapy are just a few of the many pharmacological interventions used in the management and treatment of menstrual-related headaches.</p>
      </sec>
      <sec id="article-24990.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Menstrual-related headaches are related to several important factors, mainly estrogen, which has actions involved in the serotonergic and glutamatergic systems of the CNS. This accounts for its association with headaches, where serotonin and estrogen levels are directly related. During the late secretory phase of the menstrual cycle, when estrogen is low, the production of serotonin decreases, leading to increased calcitonin gene-related peptide (CGRP) and substance P from trigeminal nerves. These substances are involved in the pathophysiology of general migraines and cause vasodilation of intracerebral vessels and sensory sensitization of the trigeminal nerve. The permeability of the blood-brain barrier increases, releasing pro-inflammatory mediators in pain-sensitive meninges.<xref ref-type="bibr" rid="article-24990.r1">[1]</xref> Around menstruation, cranial nociception is perceived as more intense due to a decrease in endogenous opioid activity, exacerbating the pain pathway.</p>
        <p>Family history should be assessed when a patient presents to a provider with a general acute headache. Genetic differences include increased expression of membranous protein channels and receptors involved in the pathophysiology of migraines.<xref ref-type="bibr" rid="article-24990.r2">[2]</xref> These individuals are more susceptible to acute migraine attacks. Other risk factors include those on certain medications, such as combined hormonal contraception. Those who are on higher doses of estrogen are more likely to suffer from MRH due to the acute falls in estrogen during the late luteal and early follicular stages of the menstrual cycle.</p>
      </sec>
      <sec id="article-24990.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Migraines affect around 12% of the general population and are more frequent in women than men. Peak migraine prevalence in women occurs between the early 30s and early 40s, and menstrual-related headaches are very common in the perimenopausal period, likely due to marked fluctuations in estrogen levels. Up to 41% of all women experience a migraine episode by their early 50s.<xref ref-type="bibr" rid="article-24990.r3">[3]</xref></p>
      </sec>
      <sec id="article-24990.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Increases in sensitivity to pain responses to both central stimuli and peripheral appear to be influenced by estrogen. Estrogen affects the sensitivity of dopaminergic and serotonin receptors and cerebral vessels to serotonin.<xref ref-type="bibr" rid="article-24990.r4">[4]</xref>&#x000a0;Activation of central nociceptive pathways from the cortex and brain stem stimulates the trigeminal vascular system, which innervates cerebral blood vessels. This leads to the release of vascular inflammatory substances, including prostaglandins, CGRP, and cytokines.<xref ref-type="bibr" rid="article-24990.r5">[5]</xref></p>
      </sec>
      <sec id="article-24990.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Menstrual-related headaches generally present similarly to nonestrogen-related migraines.<xref ref-type="bibr" rid="article-24990.r6">[6]</xref>&#x000a0;They&#x000a0;frequently have a pulsatile quality, last for about&#x000a0;1 day, are unilateral, associated with nausea, and can be disabling. Many individuals also report photophobia during attacks, which is relieved by lying down in a dark, quiet room. Menstrual-related headaches should align with the late luteal and early follicular stages of the menstrual cycle, a headache between&#x000a0;2 days before the onset of menses and the third day of menstrual bleeding.</p>
        <p>Most patients have a normal neurological exam, but some can experience cutaneous allodynia, which is the perception of pain produced by a small stimulus, such as brushing hair, touching the scalp, shaving, or wearing contact lenses, resulting in sensitization of central pain pathways, in migraine. Additionally, patients can have tenderness or difficulty resting on the allodynic side. Although rare, some studies suggest migraines can be potential risk factors for causing Bell palsy, sensorineural hearing loss, and oculomotor cranial nerve palsies.<xref ref-type="bibr" rid="article-24990.r7">[7]</xref></p>
      </sec>
      <sec id="article-24990.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Menstrual-related headaches are mainly a clinical diagnosis. In general, radiographic images are relatively normal; however, magnetic resonance imaging findings can sometimes have white matter hyperintensities, which have been linked to brain hyperperfusion, breakdown of the blood-brain-barrier, and localized cerebral edema, rather than to primary ischemia. Diffuse non-lateralizing brain hyperperfusion generally prevails during migraine attacks for more than 48 hours in the cerebral cortex, thalamus, and basal ganglia.<xref ref-type="bibr" rid="article-24990.r8">[8]</xref>&#x000a0;Radiographic imaging is only warranted when the quality, location, and duration differ from previous headaches.</p>
        <p>Migraines cause vasodilation of intracerebral vessels and sensory sensitization of the trigeminal nerve, causing inflammatory changes in the pain-sensitive meninges. This increases the blood-brain barrier's permeability, which releases proinflammatory mediators. Factors to consider when choosing the type of examination depend on the clinical indication, diagnostic performance, availability of computed tomography or magnetic resonance imaging, radiologist expertise, and patient contraindications. Any imaging of the vessels requires the use of IV contrast. Computed tomography angiogram and magnetic resonance angiogram examinations image the arteries and veins. MRH should have normal imaging and can sometimes be a diagnosis of exclusion in an emergency medicine setting.</p>
        <p>Diagnostic criteria according to&#x000a0;International Classification of Headache Disorders, 3rd edition:<xref ref-type="bibr" rid="article-24990.r9">[9]</xref>&#x000a0;</p>
        <p>Pure menstrual migraine:</p>
        <list list-type="bullet">
          <list-item>
            <p>Attacks in a menstruating woman fulfilling the criteria for migraine without aura</p>
          </list-item>
          <list-item>
            <p>Attacks occur on days&#x000a0;2 days before and last till the third day of menstruation
<list list-type="bullet"><list-item><p>Occur in at least 2 out of 3 menstrual cycles</p></list-item><list-item><p>Do&#x000a0;<bold>not&#x000a0;</bold>occur at other times of the cycle</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Menstrually related migraine:</p>
        <list list-type="bullet">
          <list-item>
            <p>Attacks in a menstruating woman fulfilling the criteria for migraine without aura</p>
          </list-item>
          <list-item>
            <p>Attacks occur on days&#x000a0;2 days before and last till the third day of menstruation
<list list-type="bullet"><list-item><p>Occur in at least 2 out of 3 menstrual cycles</p></list-item><list-item><p><bold>Can</bold> also occur at other times of the cycle</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24990.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Therapeutic lifestyle measures may be beneficial for controlling migraines, including proper sleep hygiene, healthy nutrition, routine meal schedules, regular exercise, and managing migraine triggers such as stress, alcohol, weather, and, most commonly, hormones.</p>
        <p>Managing menstrual-related headaches starts with identifying where the headache aligns with the patient&#x02019;s menstrual cycle. Suppose a patient is already on oral contraceptive pills. In that case, the headache may be prevented simply by altering her current hormone regimen by reducing the estrogen dose to limit the premenstrual decline in estrogen that precipitates the MRH.<xref ref-type="bibr" rid="article-24990.r10">[10]</xref><xref ref-type="bibr" rid="article-24990.r11">[11]</xref></p>
        <p>If women are opposed to starting hormonal therapy, are noncompliant, or contraindications exist, common abortive therapy involves using triptans, which target the direct pathophysiologic mechanism of migraines. All triptans are serotonin 1b/1d receptor agonists that prevent pain by blocking trigeminal nerve activation, inhibiting the release of vasoactive peptides, and promoting vasoconstriction.<xref ref-type="bibr" rid="article-24990.r12">[12]</xref><xref ref-type="bibr" rid="article-24990.r13">[13]</xref></p>
        <p>Most NSAIDs block COX 1/2 and can be an effective monotherapy in some women. Mefenamic acid has been extensively studied for treating acute MRH and can relieve general dysmenorrhea.<xref ref-type="bibr" rid="article-24990.r13">[13]</xref><xref ref-type="bibr" rid="article-24990.r14">[14]</xref></p>
        <p>Metoclopramide given intravenously has been proven to be as efficacious as triptan therapy when treating acute migraines in an emergency room setting.<xref ref-type="bibr" rid="article-24990.r15">[15]</xref>&#x000a0;Akathisia is a potential side effect that can be prevented with diphenhydramine; however, adding diphenhydramine does not improve migraine severity.</p>
        <p>Dihydroergotamine is an alpha-adrenergic blocker, vasoconstrictor, and potent serotonin 1b/1d receptor agonist usually reserved for severe cases of chronic intractable migraine headaches or status migrainosus.<xref ref-type="bibr" rid="article-24990.r16">[16]</xref></p>
        <p>Pharmacologic modulation of CGRP activity appears to mediate trigeminovascular pain transmission in migraine. CGRP antagonists are novel options for acute migraine treatment in patients with either insufficient response or contraindications to first-line medications.<xref ref-type="bibr" rid="article-24990.r17">[17]</xref><xref ref-type="bibr" rid="article-24990.r18">[18]</xref><xref ref-type="bibr" rid="article-24990.r19">[19]</xref></p>
        <p>Other alternative nonpharmacological interventions to consider are nerve blocks. Patients opposed to taking oral or intravenous medications may be candidates for the sphenopalatine ganglion block.<xref ref-type="bibr" rid="article-24990.r20">[20]</xref>&#x000a0;This technique involves saturating a long cotton swab in a local anesthetic and inserting the swab into the naris of the unilateral side of the patient&#x02019;s headache. In contrast, the patient is in the sniffing position. The swab should be inserted until resistance is met at the posterior wall of the nasopharynx and left in place for at least 10 minutes.</p>
        <p>Neuromodulation, such as transcutaneous electrical nerve stimulation, single-pulse transcranial magnetic stimulation, and, in extreme circumstances, surgical deactivation of migraine trigger sites, has limited data but is a therapy directed at stimulating the nervous system with an electrical current or a magnetic field. These options are generally reserved for patients with poor response or contraindications to pharmacological interventions.</p>
        <p>The use of opioids in treating MRH is generally avoided due to long-term changes in the CNS at the molecular level. Opioids lead to increased descending facilitation from the rostral ventromedial medulla and increased excitatory neurotransmission at the level of the dorsal horn, causing medication overuse headaches.<xref ref-type="bibr" rid="article-24990.r21">[21]</xref>&#x000a0;Other data suggests that chronic opioid administration increases CGRP expression in primary afferent neurons, upregulating pain afferents.</p>
      </sec>
      <sec id="article-24990.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Menstrual-related headaches have a broad differential diagnosis, including other primary headaches such as tension and cluster headaches. Treatment of MRH and other primary headaches overlap so that diagnosis can be distinguished from the patient's history and physical exam features. Some can experience cutaneous allodynia, the perception of pain produced by a small stimulus, such as brushing hair, touching the scalp, shaving, or wearing contact lenses. This results in the sensitization of central pain pathways in migraines. These episodes typically last seconds to minutes, but when they increase in intensity and frequency over time, they indicate trigeminal neuralgia, which responds well to a different therapy.</p>
        <p>Secondary headaches from trauma, vascular-related injury, metastasis, or infection can also be considered. Cerebral aneurysms, cerebral venous thrombosis, dissection syndromes, encephalitis, meningitis, intracranial hemorrhage, and temporal arteritis have different features that can usually be either ruled out or diagnosed with laboratory testing, additional head imaging, or CSF sampling.&#x000a0;Since MRH is rarely associated with aura, it is less common to be mistaken for a transient ischemic attack. Useful features for distinguishing MRH include the duration, timing, quality, comparison to previous headaches, neurological exam, and other associated symptoms during and after the attacks.</p>
      </sec>
      <sec id="article-24990.s10" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <table-wrap id="article-24990.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Acute therapy for migraine*Adverse effects in this section pertain to all triptans unless specified</title>
          </caption>
          <table style="height: 1318px; width: 1117px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 15px;">
                <td style="width: 155px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug class/Drug</bold>
</td>
                <td style="width: 8271.34px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug</bold>
</td>
                <td style="width: 10px; height: 15px;" rowspan="1" colspan="1">
<bold>Dose range</bold>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<bold>Notes</bold>
</td>
              </tr>
              <tr style="height: 142px;">
                <td style="width: 155px; height: 142px;" rowspan="1" colspan="1">Nonsteroidal anti-inflammatory drugs</td>
                <td style="width: 8271.34px; height: 142px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Aspirin<xref ref-type="bibr" rid="article-24990.r22">[22]</xref></p></list-item><list-item><p>Ibuprofen</p></list-item><list-item><p>Naproxen</p></list-item><list-item><p>Diclofenac</p></list-item><list-item><p>Diclofenac epolamine</p></list-item><list-item><p>Tolfemanic acid</p></list-item><list-item><p>Celecoxib<xref ref-type="bibr" rid="article-24990.r23">[23]</xref></p></list-item><list-item><p>Dexletoprofen</p></list-item></list>
</td>
                <td style="width: 10px; height: 142px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>900-100 mg</p></list-item><list-item><p>400-600 mg</p></list-item><list-item><p>275-825 mg</p></list-item><list-item><p>50-100 mg</p></list-item><list-item><p>65 mg</p></list-item><list-item><p>200 mg</p></list-item><list-item><p>120&#x000a0;mg</p></list-item><list-item><p>50 mg</p></list-item></list>
</td>
                <td style="width: 236px; height: 142px;" rowspan="1" colspan="1">All NSAIDs have similar efficacy&#x000a0;</td>
              </tr>
              <tr style="height: 37px;">
                <td style="width: 155px; height: 37px;" rowspan="1" colspan="1">Non-opioid analgesic</td>
                <td style="width: 8271.34px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Acetaminophen<xref ref-type="bibr" rid="article-24990.r24">[24]</xref></p></list-item></list>
</td>
                <td style="width: 10px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>1000-3000 g</p></list-item></list>
</td>
                <td style="width: 236px; height: 37px;" rowspan="1" colspan="1">Acute-life threatening hepatotoxicity at &#x0003e; 4 g/d</td>
              </tr>
              <tr style="height: 586px;">
                <td style="width: 155px; height: 586px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Sumatriptan)*<xref ref-type="bibr" rid="article-24990.r25">[25]</xref></p>
</td>
                <td style="width: 8271.34px; height: 586px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Sumatriptan (oral)</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (intranasal solution)<xref ref-type="bibr" rid="article-24990.r26">[26]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (intranasal powder)</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (spray)</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (subcutaneous)</p></list-item></list>
</td>
                <td style="width: 10px; height: 586px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>50-100&#x000a0;mg as a single dose, maximum dose: 200 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>20 mg as a single dose in 1 nostril; if symptoms persist, may repeat dose after &#x02265;2 hours, maximum dose: 40 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>22 mg as a single dose, may repeat dose after &#x02265;2 hours if symptoms persist or return, maximum dose: 44 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>10 mg as a single dose in 1 nostril. Repeat dose after &#x02265;1 hour if symptoms persist or return; maximum dose: 30 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>6 mg as a single dose, may repeat dose (usually same as the first dose) after &#x02265;1 hour if symptoms persist or return, or lesser dosage if 6 mg was not tolerated, maximum dose: 6 mg/dose; 12 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 586px;" rowspan="1" colspan="1">
<p>All formulations of triptans are <bold>contraindicated</bold> in <bold>severe hepatic impairment.</bold></p>
<p>Contraindicated in patients with cardiovascular illness as <bold>prolonged QT interval on ECG</bold> and subsequent ventricular arrhythmias, including <bold>torsades de pointes</bold> (TdP) and <bold>ventricular fibrillation,</bold>&#x000a0;are reported.</p>
<p>It may also cause&#x000a0;<bold>dizziness, lethargy, tremors, vertigo, akathisia, dystonia,</bold> and pathological laughter.</p>
<p>Other vasospasm-related events include <bold>peripheral ischemia, ischemic colitis, splenic infarction,&#x000a0;</bold>and <bold>Raynaud disease.</bold></p>
<p>It should be avoided in patients with&#x000a0;<bold>uncontrolled hypertension&#x000a0;</bold>and&#x000a0;<bold>pregnancy.</bold></p>
<p>Ocular side effects include transient and permanent <bold>blindness</bold> and significant partial <bold>vision loss.</bold></p>
<p>The use of concomitant serotonergic drugs may cause&#x000a0;<bold>serotonin syndrome.</bold></p>
<p><bold>Unpleasant taste</bold> is lower with intranasal zolmitriptan than with intranasal sumatriptan.</p>
<p>Patients who do not respond to&#x000a0;1 triptan may respond to another.</p>
<p>Naratriptan and frovatriptan have a slower&#x000a0;onset and lower efficacy.</p>
</td>
              </tr>
              <tr style="height: 108px;">
                <td style="width: 155px; height: 108px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Naratriptan)&#x000a0;</p>
</td>
                <td style="width: 8271.34px; height: 108px;" rowspan="1" colspan="1">&#x000a0;
<list list-type="bullet"><list-item><p>Naratriptan<xref ref-type="bibr" rid="article-24990.r27">[27]</xref></p></list-item></list>
</td>
                <td style="width: 10px; height: 108px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>2.5 mg as a single dose; may repeat dose after &#x02265;4 hours; maximum dose: 2.5 mg/dose; 5 mg/d.</p></list-item></list>
</td>
                <td style="width: 236px; height: 108px;" rowspan="1" colspan="1">
<p>Use within 24 hours of an ergotamine preparation or a different triptan is <bold>not advised</bold>.</p>
<p>Contraindicated with<bold> severe renal impairment</bold> (CrCl &#x0003c;15 mL/minute).</p>
</td>
              </tr>
              <tr style="height: 164px;">
                <td style="width: 155px; height: 164px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Zolmitriptan)</p>
</td>
                <td style="width: 8271.34px; height: 164px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Zolmitriptan (oral)</p></list-item></list>
<list list-type="bullet"><list-item><p>Zolmitriptan (intranasal)</p></list-item></list>
</td>
                <td style="width: 10px; height: 164px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;2.5 mg as a single dose; may repeat dose after &#x02265;2 hours; maximum dose: 5 mg/dose; 10 mg/d<xref ref-type="bibr" rid="article-24990.r28">[28]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>2.5 to 5 mg as a single dose; may repeat dose after &#x02265;2 hours; maximum: 5 mg/dose; 10 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 164px;" rowspan="1" colspan="1">Refer to the section on sumatriptan above for the side effects of triptans.</td>
              </tr>
              <tr style="height: 82px;">
                <td style="width: 155px; height: 82px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Frovatriptan)</p>
</td>
                <td style="width: 8271.34px; height: 82px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Frovatriptan</p></list-item></list>
</td>
                <td style="width: 10px; height: 82px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>2.5 mg as a single dose; may repeat dose after &#x02265;2 hours if needed; maximum dose: 2.5 mg/dose; 5 mg/d &#x000a0;</p></list-item></list>
</td>
                <td style="width: 236px; height: 82px;" rowspan="1" colspan="1">Slower onset&#x000a0;</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 155px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Almotriptan)&#x000a0;</p>
</td>
                <td style="width: 8271.34px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Almotriptan&#x000a0;</p></list-item></list>
</td>
                <td style="width: 10px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>12.5 mg as a single dose; may repeat dose after &#x02265;2 hours when needed; maximum dose: 12.5 mg/dose; 25 mg/d<xref ref-type="bibr" rid="article-24990.r29">[29]</xref></p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">Reduce dose to half with <bold>hepatic impairment&#x000a0;</bold></td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 155px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Rizatriptan)</p>
</td>
                <td style="width: 8271.34px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Rizatriptan</p></list-item></list>
</td>
                <td style="width: 10px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>5 to 10 mg as a single dose; may repeat dose after &#x02265;2 hours if needed; maximum dose: 20-30 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1"><bold>Propranolol</bold> increases rizatriptan levels by 70%. So, the dose of rizatriptan&#x000a0;must be adjusted downward for these patients.</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 155px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Eletriptan)</p>
</td>
                <td style="width: 8271.34px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Eletriptan<xref ref-type="bibr" rid="article-24990.r30">[30]</xref></p></list-item></list>
</td>
                <td style="width: 10px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>40 mg as a single dose; may repeat dose after &#x02265;2 hours if needed; maximum dose: 40 mg/dose; 80 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">Primarily metabolized by cytochrome P-450 enzyme CYP3A4. Not advised within at least 72 hours of treatment with other drugs that are <bold>potent CYP3A4 inhibitors:</bold> itraconazole, ketoconazole, clarithromycin, nefazodone,&#x000a0;troleandomycin, ritonavir, and nelfinavir.</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 155px; height: 15px;" rowspan="1" colspan="1">
<p>&#x000a0;Antiemetics</p>
</td>
                <td style="width: 8271.34px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Metoclopramide (IV, IM, oral)<xref ref-type="bibr" rid="article-24990.r31">[31]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Prochlorperazine (IV, IM)</p></list-item></list>
</td>
                <td style="width: 10px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>10-20 mg as a single dose</p></list-item></list>
<list list-type="bullet"><list-item><p>10 mg as a single dose</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">IV route is preferred for metoclopramide. Pretreat with diphenhydramine to prevent <bold>akathisia</bold> and other <bold>acute dystonic reactions.</bold></td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 155px; height: 15px;" rowspan="1" colspan="1">CGRP antagonists</td>
                <td style="width: 8271.34px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Rimegepant<xref ref-type="bibr" rid="article-24990.r18">[18]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Ubrogepant<xref ref-type="bibr" rid="article-24990.r32">[32]</xref></p></list-item></list>
</td>
                <td style="width: 10px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>75 mg every other day; maximum dose: 75 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>50 to 100 mg as a single dose; may repeat dose after &#x02265;2 hours if needed; maximum dose: 200 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Administration early in the course of a migraine attack may improve response to treatment.</p>
<p>Second-line therapy when triptans are contraindicated, poorly tolerated, or ineffective.</p>
<p>More studies are needed to establish efficacy and safety.</p>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 155px; height: 15px;" rowspan="1" colspan="1">&#x000a0;Serotonin 5-HT1F receptor agonist<xref ref-type="bibr" rid="article-24990.r33">[33]</xref></td>
                <td style="width: 8271.34px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Lasmiditan<xref ref-type="bibr" rid="article-24990.r34">[34]</xref></p></list-item></list>
</td>
                <td style="width: 10px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>50 to 100 mg as a single dose; may increase to 100 or 200 mg as a single dose if needed; repeat doses have not established efficacy.</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Administration early in the course of a migraine attack may improve response to treatment.</p>
<p>Second-line therapy when triptans are contraindicated, poorly tolerated, or ineffective.</p>
<p>A significant side effect is dizziness (9% to 17%). Wait at least 8 hours between dosing and driving or operating heavy machinery.</p>
<p>It may enhance the CNS depressant effect of alcohol.</p>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 155px; height: 15px;" rowspan="1" colspan="1">&#x000a0;Ergot derivative</td>
                <td style="width: 8271.34px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;Dihydroergotamine<xref ref-type="bibr" rid="article-24990.r35">[35]</xref></p></list-item></list>
</td>
                <td style="width: 10px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>IM:&#x000a0;1 mg as a single dose; may repeat hourly as required; maximum dose: 3 mg/d, 6 mg/week</p></list-item><list-item><p>IV:&#x000a0;1 mg as a single dose; may repeat hourly as required; maximum dose: 2 mg/d, 6 mg/week</p></list-item><list-item><p>SUBQUT: 1 mg as a single dose; may repeat&#x000a0;every 2 hours as required; maximum dose: 3 mg/d, 6 mg/week</p></list-item><list-item><p>Intranasal:&#x000a0;0.5 mg per spray: 1 spray (0.5 mg) into each nostril; repeat after 15 minutes (total of 4 sprays per dose); maximum dose: 4 sprays (1 dose)/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Use is contraindicated in severe hepatic or renal impairment as well as pregnancy or breastfeeding.</p>
<p>Also contraindicated in patients with hypertension or ischemic heart disease.</p>
<p>It should not be used within 24 hours of triptans or ergot-like agents.</p>
<p>It is also avoided when combined with potent CYP3A4 inhibitors (including azole antifungals, protease inhibitors, and some macrolide antibiotics).</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap id="article-24990.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Preventive therapy for migraine[36]</title>
          </caption>
          <table style="height: 631px; width: 902px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 15px;">
                <td style="width: 23202.9px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug Class</bold>
</td>
                <td style="width: 10px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug</bold>
</td>
                <td style="width: 173px; height: 15px;" rowspan="1" colspan="1">
<bold>Dose Range</bold>
</td>
                <td style="width: 217px; height: 15px;" rowspan="1" colspan="1">
<bold>Adverse Effects/Contraindications</bold>
</td>
              </tr>
              <tr style="height: 67px;">
                <td style="width: 23202.9px; height: 67px;" rowspan="1" colspan="1">Beta-adrenoceptor blockers<xref ref-type="bibr" rid="article-24990.r37">[37]</xref></td>
                <td style="width: 10px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Propranolol</p></list-item><list-item><p>Metoprolol</p></list-item><list-item><p>Timolol</p></list-item></list>
</td>
                <td style="width: 173px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>80-240 mg</p></list-item><list-item><p>50-150 mg</p></list-item><list-item><p>10-20 mg</p></list-item></list>
</td>
                <td style="width: 217px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Contraindicated in asthma, syncope, heart block</p></list-item></list>
</td>
              </tr>
              <tr style="height: 67px;">
                <td style="width: 23202.9px; height: 67px;" rowspan="1" colspan="1">Antidepressants</td>
                <td style="width: 10px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amitriptyline</p></list-item><list-item><p>Nortriptyline</p></list-item><list-item><p>Venlafaxine</p></list-item></list>
</td>
                <td style="width: 173px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>10-150 mg</p></list-item><list-item><p>25-100 mg</p></list-item><list-item><p>37.5-150 mg</p></list-item></list>
</td>
                <td style="width: 217px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Somnolence</p></list-item><list-item><p>Insomnia, hypertension</p></list-item></list>
</td>
              </tr>
              <tr style="height: 37px;">
                <td style="width: 23202.9px; height: 37px;" rowspan="1" colspan="1">Calcium-channel blockers</td>
                <td style="width: 10px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Verapamil<xref ref-type="bibr" rid="article-24990.r38">[38]</xref></p></list-item></list>
</td>
                <td style="width: 173px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>180-480 mg</p></list-item></list>
</td>
                <td style="width: 217px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Constipation, hypotension, edema</p></list-item></list>
</td>
              </tr>
              <tr style="height: 97px;">
                <td style="width: 23202.9px; height: 97px;" rowspan="1" colspan="1">Antiepileptic drugs<xref ref-type="bibr" rid="article-24990.r37">[37]</xref></td>
                <td style="width: 10px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Divalproex sodium</p></list-item><list-item><p>Topiramate</p></list-item><list-item><p>Gabapentin</p></list-item></list>
</td>
                <td style="width: 173px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>200-1500 mg</p></list-item><list-item><p>25-150 mg</p></list-item><list-item><p>300-1800 mg</p></list-item></list>
</td>
                <td style="width: 217px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Weight gain, thrombocytopenia, tremor</p></list-item><list-item><p>Renal calculi, amnesia, glaucoma, dysequilibrium, weight loss</p></list-item></list>
</td>
              </tr>
              <tr style="height: 97px;">
                <td style="width: 23202.9px; height: 97px;" rowspan="1" colspan="1">CGRP monoclonal antibodies</td>
                <td style="width: 10px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Erenumab</p></list-item><list-item><p>Galcanezumab</p></list-item></list>
</td>
                <td style="width: 173px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>70&#x000a0;to 140 mg every&#x000a0;4 weeks, subcutaneously</p></list-item><list-item><p>120 mg monthly subcut</p></list-item></list>
</td>
                <td style="width: 217px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Injection site reactions, muscle spasms, hypersensitivity reaction</p></list-item><list-item><p>Injection site reactions, vertigo, pruritus, constipation</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-24990.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Women who suffer from menstrual-related headaches generally have a good prognosis, and headaches usually respond well to conventional first-line pharmacological therapy. However, success sometimes depends on the reliability of predicting the regularity of a woman&#x02019;s menstrual cycle. Those with irregular cycles are usually not&#x000a0;good candidates for hormone-directed therapy.</p>
      </sec>
      <sec id="article-24990.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Although triptans are relatively safe drugs, some contraindications do exist. Cardiovascular disease should be screened for hypertension, hypercholesterolemia, smoking history, obesity, diabetes, strong family history of coronary artery disease, and menopause before initiation of therapy. Prinzmetal angina and&#x000a0;coronary artery disease are absolute contraindications due to the risk of coronary vasospasm.<xref ref-type="bibr" rid="article-24990.r39">[39]</xref>&#x000a0;A complete history of other medications should be taken to avoid possible drug-drug interactions. Patients on antidepressants are at higher risk of developing serotonin syndrome. Chronic exposure to triptans could lead to the downregulation of serotonin receptors and changes in central inhibitory pathways that translate to an impairment of antinociceptive activity and a permanent feeling of head pain.</p>
        <p>Oral contraceptive pills should not be given to patients who are older than 35 years and smoke cigarettes, have&#x000a0;2 or more risk factors for coronary artery disease or known ischemic heart valve disease, hypertension, history of venous thromboembolism, thrombogenic mutations such as antiphospholipid disease or systemic lupus erythematosus, history of stroke, breast cancer, or migraine with aura.<xref ref-type="bibr" rid="article-24990.r40">[40]</xref>&#x000a0;These are all risk factors for hypercoagulability and can ultimately lead to an embolism. Studies have shown that the use of combined hormonal contraceptives among women with migraines with aura is a higher risk of ischemic stroke.<xref ref-type="bibr" rid="article-24990.r40">[40]</xref></p>
        <p>NSAIDs are contraindicated in patients with peptic ulcer disease or at risk for gastroduodenal disease due to blocking prostaglandin, which protects the gastric mucosa. Patients at increased risk of cardiovascular disease may be restricted to NSAID use due to reduced prostaglandin I2 production by vascular endothelium with limited inhibition of prothrombotic platelet thromboxane A2 production, putting patients at higher risk for embolism. Patients with renal disease should avoid NSAID use due to the blockage of prostaglandins, which promote renal vasodilation and maintain renal perfusion.<xref ref-type="bibr" rid="article-24990.r41">[41]</xref></p>
      </sec>
      <sec id="article-24990.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients who experience frequent or severe headaches may benefit from a one-month headache diary in which they can record the duration, intensity, and location of each headache and whether it responds to therapy. Additionally, potential triggers such as food, alcohol, stressors, weather conditions, and what day of their menstrual cycle they are on can be logged. This data may provide information for avoidance and may help to determine what triggers their migraine headaches and what makes them better.</p>
      </sec>
      <sec id="article-24990.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Coordinating care between healthcare professionals is essential to patient care, especially when modulating a patient's pharmacological therapy. Whether a woman's menstrual headaches are being managed by a neurologist or in the emergency setting, it is important to coordinate with all clinicians. Patients should see the same clinician or, at the very least, a provider in the same health network where other specialists can easily access the electronic medical record. Having old records is an invaluable tool to see if there are any medication regimen changes, history differences, or physical exam findings.</p>
        <p>Whether a neurologist, an emergency clinician, or another specialist is currently treating the patient, improving care coordination with the primary care clinician would minimize the adverse effects of new interventions. For example, suppose a woman with an acute migraine presents and does not know that she has an underlying cardiac problem and is given triptan therapy. In that case, this can lead to fatal coronary vasospasm. Coordinating medication regimens with input from a pharmacist can be a very helpful interprofessional strategy.</p>
        <p>Monitoring a patient's headache calendar and coordinating the dates with the patient's menstrual cycle is key to targeting treatment. If there are clear differences in the pattern of quality, location, and timing in the patient's previous recorded headaches, it can suggest an alternate diagnosis. Collaborating care can ultimately change patient management and help identify if the patient needs outpatient therapy versus emergent treatment. Nursing also provides crucial care, coordinating actions between various disciplines and providing necessary patient counseling.</p>
        <p>The importance of communication between the interprofessional team cannot be undervalued as patients started on combined hormonal contraception can have serious adverse effects. Patients being treated for acute migraines that have worsened may need to change their long-term treatment regimen, but not before clinicians and other associated healthcare providers coordinate therapies.</p>
      </sec>
      <sec id="article-24990.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24990&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24990">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/womens-health/menstrual-related-headache-period-headache/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24990">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24990/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24990">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24990.s16">
        <title>References</title>
        <ref id="article-24990.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frederiksen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Bekker-Nielsen Dunbar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Snoer</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Deen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Edvinsson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis.</article-title>
            <source>Headache</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>6</issue>
            <fpage>1132</fpage>
            <page-range>1132-1164</page-range>
            <pub-id pub-id-type="pmid">32293721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brunklaus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schorge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Ghanty</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gardiner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Palma</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Symonds</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Lal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zuberi</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>SCN1A variants from bench to bedside-improved clinical prediction from functional characterization.</article-title>
            <source>Hum Mutat</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>363</fpage>
            <page-range>363-374</page-range>
            <pub-id pub-id-type="pmid">31782251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burch</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and Treatment of Menstrual Migraine and Migraine During Pregnancy and Lactation: A Narrative Review.</article-title>
            <source>Headache</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>200</fpage>
            <page-range>200-216</page-range>
            <pub-id pub-id-type="pmid">31579938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paredes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cantillo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Candido</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Knezevic</surname>
                <given-names>NN</given-names>
              </name>
            </person-group>
            <article-title>An Association of Serotonin with Pain Disorders and Its Modulation by Estrogens.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Nov</month>
            <day>15</day>
            <volume>20</volume>
            <issue>22</issue>
            <pub-id pub-id-type="pmid">31731606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>The neurobiology of migraine.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2010</year>
            <volume>97</volume>
            <fpage>99</fpage>
            <page-range>99-108</page-range>
            <pub-id pub-id-type="pmid">20816413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pescador Ruschel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>De Jesus</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <chapter-title>Migraine Headache</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>7</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">32809622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Fuh</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Migraine and Risk of Ocular Motor Cranial Nerve Palsies: A Nationwide Cohort Study.</article-title>
            <source>Ophthalmology</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>191</fpage>
            <page-range>191-7</page-range>
            <pub-id pub-id-type="pmid">26460000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamedani</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Peterlin</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Mosley</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Coker</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Jack</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Knopman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gottesman</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Migraine and white matter hyperintensities: the ARIC MRI study.</article-title>
            <source>Neurology</source>
            <year>2013</year>
            <month>Oct</month>
            <day>08</day>
            <volume>81</volume>
            <issue>15</issue>
            <fpage>1308</fpage>
            <page-range>1308-13</page-range>
            <pub-id pub-id-type="pmid">23975874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <article-title>Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</article-title>
            <source>Cephalalgia</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-211</page-range>
            <pub-id pub-id-type="pmid">29368949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandes</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>The influence of estrogen on migraine: a systematic review.</article-title>
            <source>JAMA</source>
            <year>2006</year>
            <month>Apr</month>
            <day>19</day>
            <volume>295</volume>
            <issue>15</issue>
            <fpage>1824</fpage>
            <page-range>1824-30</page-range>
            <pub-id pub-id-type="pmid">16622144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calhoun</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>A novel specific prophylaxis for menstrual-associated migraine.</article-title>
            <source>South Med J</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>97</volume>
            <issue>9</issue>
            <fpage>819</fpage>
            <page-range>819-22</page-range>
            <pub-id pub-id-type="pmid">15455962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tabeeva</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Evdokimova</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Shagbazyan</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>[The efficacy of the second generation triptan migrepam in the treatment of migraine attacks: results of the comparative study].</article-title>
            <source>Zh Nevrol Psikhiatr Im S S Korsakova</source>
            <year>2019</year>
            <volume>119</volume>
            <issue>12</issue>
            <fpage>20</fpage>
            <page-range>20-28</page-range>
            <pub-id pub-id-type="pmid">31994510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Waili</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo.</article-title>
            <source>Eur J Med Res</source>
            <year>2000</year>
            <month>Apr</month>
            <day>19</day>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>176</fpage>
            <page-range>176-82</page-range>
            <pub-id pub-id-type="pmid">10799353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacGregor</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Prevention and treatment of menstrual migraine.</article-title>
            <source>Drugs</source>
            <year>2010</year>
            <month>Oct</month>
            <day>01</day>
            <volume>70</volume>
            <issue>14</issue>
            <fpage>1799</fpage>
            <page-range>1799-818</page-range>
            <pub-id pub-id-type="pmid">20836574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfaffenrath</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rehm</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Migraine in pregnancy: what are the safest treatment options?</article-title>
            <source>Drug Saf</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>383</fpage>
            <page-range>383-8</page-range>
            <pub-id pub-id-type="pmid">9825951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zagami</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Treatment of the Patient with Refractory Headache.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2018</year>
            <month>Mar</month>
            <day>19</day>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>23</fpage>
            <pub-id pub-id-type="pmid">29556828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Ge</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Assaid</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gottwald</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>MacGregor</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Mannix</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>van Oosterhout</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Koppenhaver</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lines</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Michelson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine.</article-title>
            <source>Cephalalgia</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>148</fpage>
            <page-range>148-61</page-range>
            <pub-id pub-id-type="pmid">25926620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Croop</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Conway</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Forshaw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Coric</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Aug</month>
            <day>31</day>
            <volume>394</volume>
            <issue>10200</issue>
            <fpage>737</fpage>
            <page-range>737-745</page-range>
            <pub-id pub-id-type="pmid">31311674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Croop</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dubowchik</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Conway</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Coric</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jul</month>
            <day>11</day>
            <volume>381</volume>
            <issue>2</issue>
            <fpage>142</fpage>
            <page-range>142-149</page-range>
            <pub-id pub-id-type="pmid">31291516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Binfalah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alghawi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shosha</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alhilly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bakhiet</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sphenopalatine Ganglion Block for the Treatment of Acute Migraine Headache.</article-title>
            <source>Pain Res Treat</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>2516953</fpage>
            <pub-id pub-id-type="pmid">29862074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunasekera</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Akhlaghi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sun-Edelstein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heywood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Overuse of opioids for acute migraine in an Australian emergency department.</article-title>
            <source>Emerg Med Australas</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>763</fpage>
            <page-range>763-768</page-range>
            <pub-id pub-id-type="pmid">32270597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biglione</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gitin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gorelick</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Hennekens</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers.</article-title>
            <source>Am J Med</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>133</volume>
            <issue>4</issue>
            <fpage>412</fpage>
            <page-range>412-416</page-range>
            <pub-id pub-id-type="pmid">31712099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Munjal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brand-Schieber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.</article-title>
            <source>Headache</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-70</page-range>
            <pub-id pub-id-type="pmid">31647577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiffen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Knaggs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Dec</month>
            <day>27</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD012227</fpage>
            <pub-id pub-id-type="pmid">28027389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derry</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>May</month>
            <day>28</day>
            <volume>2014</volume>
            <issue>5</issue>
            <fpage>CD009108</fpage>
            <pub-id pub-id-type="pmid">24865446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derry</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan (intranasal route of administration) for acute migraine attacks in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Feb</month>
            <day>15</day>
            <volume>2012</volume>
            <issue>2</issue>
            <fpage>CD009663</fpage>
            <pub-id pub-id-type="pmid">22336867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Havanka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dahl&#x000f6;f</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pop</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Whitehouse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hassani</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group.</article-title>
            <source>Clin Ther</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>970</fpage>
            <page-range>970-80</page-range>
            <pub-id pub-id-type="pmid">10972633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapoport</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ramadan</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Adelman</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Elkind</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kudrow</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Earl</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.</article-title>
            <source>Neurology</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>1210</fpage>
            <page-range>1210-8</page-range>
            <pub-id pub-id-type="pmid">9371896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Zanchin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Geraud</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Klippel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Diaz-Insa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gobel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ivanoff</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Falques</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fortea</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan.</article-title>
            <source>Cephalalgia</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>383</fpage>
            <page-range>383-91</page-range>
            <pub-id pub-id-type="pmid">18294251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Oldman</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>McQuay</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Eletriptan for acute migraine.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2001</year>
            <issue>3</issue>
            <fpage>CD003224</fpage>
            <pub-id pub-id-type="pmid">11687056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelley</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others.</article-title>
            <source>Headache</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>292</fpage>
            <page-range>292-306</page-range>
            <pub-id pub-id-type="pmid">22309235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Ailani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Finnegan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Szegedi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trugman</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>Nov</month>
            <day>19</day>
            <volume>322</volume>
            <issue>19</issue>
            <fpage>1887</fpage>
            <page-range>1887-1898</page-range>
            <pub-id pub-id-type="pmid">31742631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuca</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wietecha</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Dozier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <collab>COL MIG-301 Study Group</collab>
            </person-group>
            <article-title>Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Dec</month>
            <day>11</day>
            <volume>91</volume>
            <issue>24</issue>
            <fpage>e2222</fpage>
            <page-range>e2222-e2232</page-range>
            <pub-id pub-id-type="pmid">30446595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wietecha</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dennehy</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Kuca</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Case</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gaul</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.</article-title>
            <source>Brain</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>142</volume>
            <issue>7</issue>
            <fpage>1894</fpage>
            <page-range>1894-1904</page-range>
            <pub-id pub-id-type="pmid">31132795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Winner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Jeleva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hocevar-Trnka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shrewsbury</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD<sup>&#x000ae;</sup> ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.</article-title>
            <source>Headache</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>1214</fpage>
            <page-range>1214-1226</page-range>
            <pub-id pub-id-type="pmid">34363701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lowder</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Medications for migraine prophylaxis.</article-title>
            <source>Am Fam Physician</source>
            <year>2006</year>
            <month>Jan</month>
            <day>01</day>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-8</page-range>
            <pub-id pub-id-type="pmid">16417067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Prophylaxis of migraine headache.</article-title>
            <source>CMAJ</source>
            <year>2010</year>
            <month>Apr</month>
            <day>20</day>
            <volume>182</volume>
            <issue>7</issue>
            <fpage>E269</fpage>
            <page-range>E269-76</page-range>
            <pub-id pub-id-type="pmid">20159899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markley</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Verapamil and migraine prophylaxis: mechanisms and efficacy.</article-title>
            <source>Am J Med</source>
            <year>1991</year>
            <month>May</month>
            <day>17</day>
            <volume>90</volume>
            <issue>5A</issue>
            <fpage>48S</fpage>
            <page-range>48S-53S</page-range>
            <pub-id pub-id-type="pmid">2039020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathew</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk.</article-title>
            <source>Headache</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>1421</fpage>
            <page-range>1421-1426</page-range>
            <pub-id pub-id-type="pmid">31318457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Champaloux</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Monsour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Whiteman</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Marchbanks</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Jamieson</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2017</year>
            <month>May</month>
            <volume>216</volume>
            <issue>5</issue>
            <fpage>489.e1</fpage>
            <page-range>489.e1-489.e7</page-range>
            <pub-id pub-id-type="pmid">28034652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24990.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huerta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Castellsague</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Varas-Lorenzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Rodr&#x000ed;guez</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>531</fpage>
            <page-range>531-9</page-range>
            <pub-id pub-id-type="pmid">15754275</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
